ArticleMolecular genetics & genomic medicine2025
Identification of Compound Heterozygous Variants in OBSCN Gene Associated With Rhabdomyolysis: A Case Report.
Article in Molecular genetics & genomic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe obscurin protein encoded by the OBSCN gene is an important structural protein in the regulation of myocyte sarcoplasmic nodule stability and sarcoplasmic reticulum function and is particularly closely associated with calcium ion (Ca
methodsWe performed whole exome sequencing on a patient with exercise-induced rhabdomyolysis to identify possible causative gene variants. In addition, functional prediction of the pathogenicity of the variants was performed by combining multiple bioinformatics analysis tools and in-depth analyses with clinical phenotypes and family history.
resultsThe patient carried compound heterozygous variants, including c.21184C>T (nonsense variant) and c.15610+12C>T (intronic splicing variant). The c.21184C>T variant resulted in a premature termination of the protein, was not included in population-based databases, and was supported by multiple prediction tools as a potentially pathogenic variant. The c.15610+12C>T variant was also absent in the gnomAD_EAS database and predicted to disturb normal splicing, potentially creating a novel donor site. The pathogenicity of the variant is further supported by the fact that the patient's mother, with a homozygous OBSCN variant, also exhibited exercise-induced myalgia. Clinically, the patient presented with exercise-induced rhabdomyolysis accompanied by significant serum creatine kinase elevation, muscle pain, and MRI-demonstrated muscle edema of both lower limbs without significant muscle weakness or cardiac abnormalities.
conclusionWe report the first case of rhabdomyolysis in China caused by OBSCN gene variants. This finding further extends the spectrum of the OBSCN gene variants. It also provides an important basis for genetic counseling and helps in the early diagnosis and management of similar cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.